Site Selection Magazine
Life Sciences Report
by WANYNE ROPER, President, SCBIO
Rumbling bulldozers had barely scraped the sandy loam at the groundbreaking of Nephron Pharmaceuticals’ new South Carolina plant when CEO Lou Kennedy began talking about doing more.“This could be bigger and better than we dreamed,” she told The State newspaper. She was already working with University of South Carolina researchers in nearby Columbia to make research and development a key at the new $313-million facility with the goal of expanding product lines.